Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14251 - 14275 of 14860 in total
LY518674 has been used in trials studying the treatment of Metabolic Syndrome X.
Investigational
Experimental
Experimental
Experimental
Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).
Investigational
Daniquidone has been used in trials studying the treatment of Neoplasms.
Investigational
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Esatenolol is a beta blocker.
Experimental
Experimental
Experimental
APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life. APL-9 is designed...
Investigational
Matched Description: … mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and
An anticholesteremic agent.
Experimental
Displaying drugs 14251 - 14275 of 14860 in total